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means that 55% of all subjects who will not develop
the disease will be classiﬁed falsely. In a population in
which 95% of the individuals will not develop the dis-
ease, as in the study of Yang et al., this means that 52%
will undergo unnecessary preventive treatment. When a
sensitivity of 0.90 is chosen, the percentage of all subjects
who are unnecessarily selected is 73%. In comparison,
the sensitivity and speciﬁcity of mammography in a large
population–based breast cancer screening program were
0.75 and 0.92, respectively (Carney et al. 2003). Thus,
the multiplex genetic tests of Yang et al. are by no means
efﬁcient screening strategies.
In conclusion, the clinical usefulness of genetic testing
should be evaluated by ROC analysis. Using this ap-
proach for the data of Yang et al., we found that the
discriminative ability of the multiplex genetic test in-
creased by the addition of more genes but that its per-
formance for use as a screening instrument was rather
inefﬁcient. It remains to be investigated whether these
results are representative of the prediction of common
disease by multiplex genetic tests that include genetic
factors with low mutation prevalence and low relative
risks. In that case, alternative statistical strategies are
needed to increase the potential clinical application of
selective genetic testing.
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Revisiting the Clinical Validity of Multiplex Genetic
Testing in Complex Diseases: Reply to Janssens et al.
To the Editor:
We appreciate the comments by Janssens and her as-
sociates (2004 [in this issue]) regarding our study on the
use of likelihood ratios to improve the prediction of
complex diseases by testing for multiple-susceptibility
genes (Yang et al. 2003). As Janssens et al. correctly
point out, our study considers only the predicted prob-
ability of disease for subjects who have all positive test-
ing results, and this is likely to be an infrequent occur-
rence. We think that the suggestion made by Janssens et
al. to use receiver-operating–characteristic (ROC) curves
to assess multiple genetic testing is very useful. The ROC
curves provide a valuable way of evaluating the accuracy
and discriminatory ability of diagnostic tests (Hanley
1989). Janssens et al. use the ROC curves to assess the
classiﬁcation of patients into a disease group, but mul-
tiplex genetic testing is likely also to be of value in iden-
tifying people who are at lower-than-average risk for
developing a particular disease. This might allow them
to put off receiving a more expensive intervention for
some time—for example, to defer mammography for
breast cancer detection for 10 years (Fletcher 1997) or
to avoid screening for prostate cancer until 60 years
of age (Harris and Lohr 2002).
The predictive value of combining tests obviously does
depend on the relative risk associated with each com-
ponent test, with a bigger effect resulting from tests that
make larger independent contributions. Janssens et al.
suggest that an odds ratio of 1.5–1.7 for each test is
more likely than an odds ratio of 3.5. This might be
true, but we do not yet know what the relative frequency
of genes of larger or smaller effect will turn out to be
for any common multifactorial disease. We used ﬁve ge-
netic tests and an environmental factor as a simpliﬁed
illustration in our analysis, but, in the near future, 50
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or 100 genetic tests might be available formany common
diseases. If there are numerous predisposing alleles and
each has an independent odds ratio of only 1.5–1.7, the
overall effect would still be substantial. We simulated
models of 10, 15, and 20 genes with a risk of 1.5–1.7
each and found the areas under the ROC curves (AUCs)
to be 0.70, 0.74, and 0.77, respectively. The discrimi-
natory ability of 20 gene tests, each with an odds ratio
of 1.5–1.7, is comparable with the test of total choles-
terol level for prediction of coronary heart disease (Wil-
son et al. 1998). The effect would be even greater if only
5% or 10% of all alleles tested had odds ratios in the
range of 2.5–3.5 or if we could identify combinations
of a few genes and/or gene-environment interactions that
are strong predictors of the disease.
The comments of Janssens et al. also raise several in-
teresting points regarding different perspectives on mul-
tiple genetic testing. Epidemiologic studies, including
those on the utility of ROC curves for screening, provide
a useful population perspective. In contrast, clinicians
usually focus on individual patients rather than on the
population as a whole, and this focus will be enhanced
by the development of personalized genomic medicine
(Roses 2000; Jain 2002). It is true that no more than a
few people per million might turn out to have a very
high risk deﬁned by positive results for multiple genetic
tests for a particular disease. However, it might be very
important to these few people to know that they are at
high risk if an intervention is available to prevent the
disease. Our likelihood-ratio–based method provides an
approach that is useful for individual patients and their
physicians in predicting the probability of developing
disease.
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Impact of Genotyping Errors on Type I Error Rate of
the Haplotype-Sharing Transmission/Disequilibrium
Test (HS-TDT)
To the Editor:
In a recent issue of the Journal, Zhang et al. (2003)
proposed a haplotype-sharing transmission/disequilib-
rium test (HS-TDT) for the null hypothesis of no linkage
or no association between a disease and a chromosomal
region in which several tightly linked markers have been
typed. Their method is applicable to data of nuclear
families without phase information. The general idea of
their approach is to compare the similarity of the trans-
mitted haplotypes with the similarity of the nontrans-
mitted haplotypes. If the chromosomal region contains
a susceptibility locus, it is expected that the haplotypes
being transmitted to affected children are more similar
than parental haplotypes that have not been transmitted.
This reasoning seems intuitively appealing. However, it
may be supposed that a larger observed similarity for
transmitted than for nontransmitted haplotypes is not
necessarily due to the presence of a disease-susceptibility
locus but can be a consequence of undetected genotyping
errors. The proportion of genotyping errors that result
in a Mendelian inconsistency (MI) is relatively small for
family trios (Gordon et al. 1999). More important, in
the context of HS-TDT, is the fact that the chance to
detect a genotyping error differs for transmitted and
nontransmitted haplotypes. Obviously, mistyping of an
allele on a nontransmitted parental haplotype can never
